Actavis Pharma R&D investment for the second quarter 2013 increased to $103.7 million, and selling and marketing expenses for the second quarter 2013 increased to $160.9 million, primarily as a result of the inclusion of legacy Actavis results.
Actavis Pharma's adjusted gross margin increased from 47.6 percent in the second quarter of 2012 to 51.9 percent in the second quarter of 2013, primarily due to Anda's distribution of Lidoderm®, increased margins on our generic version of Concerta® as a result of our contractual arrangement with Ortho-McNeil-Janssen and higher other revenue.
Specialty Brands Segment InformationThree Months EndedSix Months EndedJune 30,June 30,(Unaudited; $ in millions)2013201220132012Product sales
144.8119.3275.5228.9Operating expenses:Cost of sales
34.428.764.254.5Research and development
31.925.965.258.3Selling and marketing
76.2%75.9%76.7%76.2%Actavis Specialty Brands net revenue increased 21 percent to $144.8 million in the second quarter. The increase was primarily due to higher sales of key promoted products including Generess® Fe, Rapaflo®, Crinone® and the addition of Kadian®.
|SOURCE Actavis, Inc.|
Copyright©2012 PR Newswire.
All rights reserved